Alternative Data Market Size, Share, Growth Analysis, By Type (Credit & Debit Card Transactions, Email Receipts), By Industry (Automotive, BFSI), By End Use (Hedge Fund Operators, Investment Institutions), By Region - Industry Forecast 2025-2032

Global Alternative Data Market size was valued at USD 10.18 Billion in 2023 and is poised to grow from USD 14.79 Billion in 2025 to USD 292.59 Billion by 2032, growing at a CAGR of 45.23 % in the forecast period (2025-2032).

The alternative data industry is expected to witness a high growth phase in the near future. The market is quite fragmented, with many small-scale companies and start-ups. In order to gain competitive advantage, the key market players are also focusing on achieving optimum accuracy in data sets and developing premium quality and high-value datasets through Research and Development (R&D) Studies by constantly innovating themselves. With respect to many of the types of data considered, such as sentimental data, footprint data, transaction data and others, we expect the threat of substitutes of alternative data would be low since a direct alternative in the market does not exist. Also, the web scraped and public domain dataset/verbiage like Annual reports, financials, etc., are turning out to be obsolete for better decision making as strategy managers start venturing toward alternative data to frame business strategies. '1010Data', 'Advan', 'Dataminr', 'Earnest Research', 'M Science', 'Preqin', 'RavenPack', 'Thinknum Alternative Data', 'UBS Evidence Lab', 'YipitData ', 'Beijing Tendcloud Tianxia Technology ', 'Convergence ', 'Geotab Inc.', 'Intrinio ', 'Japan Exchange Group '

Growing Application of Alternate Data in Hedge Funds

Implementation of Technology to Handle Large Volume Data: Bioinformatics tools allow the identification of new biomarkers based on changes in human physiology highlighted by Alternative Data results. Biomarkers have utility for in-vitro diagnostics, environmental toxicology screening and drug discovery and development platform methods. Over the past decade, the omics revolution has amplified Alternative Data usages in biomedical fields.

North America is dominating the market due to increasing adoption of alternative data, resulting in the expansion of alternative data market size. The sizeable market share of the region is attributed to a number of market players such as Advan, Eagle Alpha, M Science and UBS Evidence Lab. This factor along with the early adoption of alternative data from range of industry verticals makes this nation most prominent holder in market. Today, over 70% of American asset managers want to include alternative data in their investment strategy. Business alliances and purchases from Nasdaq and S&P Global Platts will also help spur the growth of the regional market. These are raising it above otherwise competitive regions.